Invitrogen™ Zuberitamab Recombinant Monoclonal Antibody

Zuberitamab, also known by its code name HS-006 and brand name Anruixi, is a biosimilar of rituximab that targets the CD20 antigen on B-cells. The CD20 gene, also known as MS4A1, encodes a B cell-specific membrane-bound protein that plays a crucial role in B cell development and function. Located on chromosome 11q12 in humans, the MS4A1 gene spans 16 kb and includes eight exons. CD20 is a part of the membrane-spanning 4-domain family, subfamily A (MS4A), which encompasses 18 tetraspan proteins. The prominent CD20 mRNA variant is 2.8 kb long, although other shorter variants exist. This phosphoprotein, approximately 33-37 kDa, is expressed on the surface of almost all normal and malignant B cells, making it an ideal target for therapeutic antibodies like rituximab. CD20 is known to interact with several proteins such as CD40, MHCII, and CD81, playing a role in B cell receptor signaling and other immune processes. Despite its widespread clinical use in B cell depletion therapies, the precise biological function of CD20 remains partly unresolved.